Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors

International Journal of Cancer

Volumn 129, Issue 11, 2011, Pages 2533-2542

  Eisenberg, Burton L ^a   Trent, Jonathan C ^b  

^a NORRIS COTTON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

adjuvant; GIST; imatinib; neoadjuvant; tyrosine kinase inhibitor

Indexed keywords

IMATINIB; PLACEBO;

ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GRANULOCYTOPENIA; HEART MUSCLE ISCHEMIA; HUMAN; MITOSIS INDEX; NEUTROPENIA; ONCOGENE C KIT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PRURITUS; RECURRENCE FREE SURVIVAL; TUMOR RECURRENCE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE MANAGEMENT; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOADJUVANT THERAPY; PIPERAZINES; PYRIMIDINES;

EID: 80053296615     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26234     Document Type: Article

References (60)

1. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG,. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202: 623-9.
2. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC,. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005; 41: 2868-72. (Pubitemid 41713125)
3. Mucciarini C, Rossi G, Bertolini F, Valli R, Cirilli C, Rashid I, Marcheselli L, Luppi G, Federico M,. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007; 7: 230.
4. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG,. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005; 103: 821-9. (Pubitemid 40216412)
5. Nishida T, Hirota S,. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000; 15: 1293-301.
6. Rubio J, Marcos-Gragera R, Ortiz MR, Miro J, Vilardell L, Girones J, Hernandez-Yague X, Codina-Cazador A, Bernado L, Izquierdo A, Colomer R,. Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. Eur J Cancer 2007; 43: 144-8. (Pubitemid 46054472)
7. Tran T, Davila JA, El Serag HB,. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100: 162-8. (Pubitemid 41623284)
8. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG,. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289-93. (Pubitemid 41377450)
9. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad TG, Matsuzawa Y, et al,. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80. (Pubitemid 28067289)
10. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, et al,. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10. (Pubitemid 36159485)
11. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y,. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-7. (Pubitemid 37070684)
12. Corless CL, Heinrich MC,. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008; 3: 557-86. (Pubitemid 351488293)
13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Soft tissue sarcoma. V.2.2010. Accessed March 24, 2011.
14. Casali PG, Blay JY,. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5: v98-102.
15. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF,. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8. (Pubitemid 30043939)
16. Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR,. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003; 98: 2693-9. (Pubitemid 37509535)
17. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, Van Oosterom A, Hogendoorn PC, van Glabbeke M, Bertulli R, Judson I,. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34. (Pubitemid 39296599)
18. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, et al,. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-5. (Pubitemid 351264357)
19. DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, et al,. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-104.
20. Gleevec/Glivec prescribing information. Accessed March 24, 2011.
21. Cohen MH, Cortazar P, Justice R, Pazdur R,. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist 2010; 15: 300-7.
22. European Medicines Agency. Glivec. Available at:. Accessed March 24, 2011.
23. Bucher P, Egger JF, Gervaz P, Ris F, Weintraub D, Villiger P, Buhler LH, Morel P,. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 2006; 32: 310-4.
24. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H,. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90: 332-9. (Pubitemid 36324113)
25. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM,. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77.
26. Dei Tos AP, Rossi S, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Amore P, Casali PG,. The natural history of imatinib-naive GIST: A retrospective analysis of 929 cases with long-term follow-up. J Clin Oncol (Meeting Abstracts) 2009; 27: 10555.
27. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ,. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7. (Pubitemid 29025244)
28. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, et al,. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-65. (Pubitemid 34747864)
29. Joensuu H,. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-9.
30. Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, von Mehren M, Maki RG, Pisters PW, DeMatteo RP, American College of Surgeons Oncology Group. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol (Meeting Abstracts) 2010; 28: 10006.
31. Gold JS, Gonen M, Gutierrez A, Broto JM, Garcia-del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, DeMatteo RP,. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045-52.
32. Goldstein D, Lee C, Hui Y, Shah B, Yip D, McArthur GA,. Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib. J Clin Oncol (Meeting Abstracts) 2010; 28: 10054.
33. Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engstrom K, Stierner U, Wangberg B, Jansson S, Ahlman H, Kindblom LG, Nilsson B,. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-4. (Pubitemid 37026425)
34. Castillo-Sang M, Mancho S, Tsang AW, Gociman B, Almaroof B, Ahmed MY,. A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature. World J Surg Oncol 2008; 6: 50.
35. Efremidou EI, Liratzopoulos N, Papageorgiou MS, Romanidis K,. Perforated GIST of the small intestine as a rare cause of acute abdomen: Surgical treatment and adjuvant therapy. Case report. J Gastrointestin Liver Dis 2006; 15: 297-9. (Pubitemid 44483101)
36. Nilsson B, Sjolund K, Kindblom LG, Meis-Kindblom JM, Bumming P, Nilsson O, Andersson J, Ahlman H,. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96: 1656-8. (Pubitemid 46847213)
37. DeMatteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M, von Mehren M, Pisters P, Brennan MF, Ballman KV,. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. ASCO 2008 Gastrointestinal Cancers Symposium: January 25-27; Orlando, FL. (Abstract 8).
38. Kang B, Sr., Lee J, Ryu M, Im S, Park S, Kang W, Kim T, Oh D, Jung K, Kang Y,. A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J Clin Oncol (Meeting Abstracts) 2009; 27: e21515.
39. Li J, Gong FJ, Li J, Wu WA, Shen L,. Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: Analysis from a single-center contrast study. J Clin Oncol (Meeting Abstracts) 2009; 27: 10556.
40. Corless CL, Schroeder A, Griffith D, Town A, Mcgreevey l, Harrell P, Shiraga S, Bainbridge T, Morich, J, Heinrich MC,. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005: 23: 5357-64. (Pubitemid 46206989)
41. Debiec-Rychter M, Cools J, Dumez, H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen, H, Roesel J, Hagemeijer A, van Oosterom A, Marynen P,. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005: 128: 270-9. (Pubitemid 40431080)
42. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey, LS, Chen, CJ, van den Abbeele, AD, Druker, BJ, Kiese B, Eisenberg B, et al,. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003: 21: 4342-9. (Pubitemid 46621810)
43. Li J, Gong JF, Wu AW, Shen L,. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011; 37: 319-24.
44. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P, Pollock RE, Benjamin RS, Trent JC,. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009; 16: 910-9.
45. European Organization for Research and Treatment of Cancer, Italian Sarcoma Group, Federation Nationale des Centres de Lutte Contre le Cancer, Grupo Espanol de Investigacion en Sarcomas. EORTC 62024. NCT Identifier: NCT00103168. Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor. Accessed March 24, 2011.
46. Scandinavian Sarcoma Group. NCT Identifier: NCT00116935. Study comparing 12 months versus 36 months of imatinib in the treatment of gastrointestinal stromal tumor (GIST). Accessed March 24, 2011.
47. Novartis Pharmaceuticals. NCT Identifier: NCT00867113. Five year adjuvant imatinib mesylate (Gleevec®) in gastrointestinal stromal tumor (GIST). Accessed March 24, 2001.
48. Ciresa M, D'Angelillo RM, Ramella S, Cellini F, Gaudino D, Stimato G, Fiore M, Greco C, Nudo R, Trodella L,. Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report. Tumori 2009; 95: 236-9.
49. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M,. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99: 42-7.
50. Hou YY, Zhou Y, Lu SH, Qi WD, Xu C, Hou J, Tan YS,. Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. World J Gastroenterol 2009; 15: 1910-3.
51. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, et al,. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24. (Pubitemid 44954266)
52. DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR,. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245: 347-52. (Pubitemid 46673128)
53. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, et al,. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
54. Okuda H, Tanaka H, Ueno M, Shitani M, Nasuno M, Suzuki C, Nishimura S, Kimura H, Yonezawa K, Abe T, Yoshida Y, Kawabata M,. [A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively]. Gan To Kagaku Ryoho 2005; 32: 1941-4.
55. Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK,. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32: 961-3. (Pubitemid 44615593)
56. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Strobel P, Reichardt P, Wardelmann E,. Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol (Meeting Abstracts) 2009; 27: 10550.
57. Cassier PA, Blesius AA, Perol D, Ray-Coquard I, Adenis A, Bui B, Bertucci F, Rios M, Le Cesne A, Blay J,. Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial. J Clin Oncol (Meeting Abstracts) 2009; 27: 10551.
58. Technische Universität München. NCT Identifier: NCT00112632. Imatinib mesylate in treating patients with locally advanced gastrointestinal stromal tumor. Accessed March 24, 2011.
59. Blesius A, Cassier PA, Bertucci F, Fayette J, Ray-Coquard I, Bui B, Adenis A, Rios M, Cupissol D, Perol D, Blay JY, Le Cesne A,. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 2011; 11: 72.
60. Casali PG, Joensuu H, Martin Broto J, Garcia del Muro X, Blay J, May C, Pustowka A, Reichardt P,. Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). J Clin Oncol (Meeting Abstracts) 2010; 28: TPS332.